The grant of SEK 150,000 from Vinnova will be used for a development of a regulatory plan and to evaluate the commercial potential of the antibody-based PET imaging for Alzheimer´s disease. This is a collaborative research project within Uppsala Berzelii Technology Centre for Neurodiagnostics; between the Molecular Geriatrics group at the Uppsala University and BioArctic.
The research project is based on BioArctic’s antibodies and a new technology to increase brain uptake of antibodies across the blood-brain barrier (BBB). The results from the research project have shown an up to 100-fold increased antibody concentration in the brain. In the first study, the bispecific antibody was used as a positron emission tomography (PET) biomarker to image amyloid-beta pathology, the characteristic hallmark of the Alzheimer’s disease brain (Sehlin et al. 2016). To the company’s knowledge, this is the first successful central nervous system PET radioligand based on an antibody.
The even wider potential for the BBB technology is in immunotherapy for neurodegenerative diseases or brain tumors, where efficacy of the therapeutic antibody is believed to be restricted due to low penetration into the brain.
“We are very grateful for the additional grant for this important research project which also is external quality mark. We will develop this PET tracer further to be used as biomarker in drug development and potentially future diagnostic tool in Alzheimer patients, says Gunilla Osswald, CEO of BioArctic AB.
BioArctic is developing a completely new treatment (disease modifying) for Alzheimer’s disease. One major challenge is the limitations of biomarkers reflecting disease pathology, stage and severity. Thus, there is a need for biomarkers to evaluate the disease modifying efficacy of drugs in clinical trials.
For more information, please contact:
Gunilla Osswald, CEO
Telephone +46 (0)8 695 6930